Articles related to HEALTHCARE ACCESS

Patients report significant weight loss with compounded semaglutide that would be difficult to maintain if forced to discontinue treatment due to cost barriers, despite manufacturer discount programs reducing brand-name medication costs to approximately $499 monthly.

A Lilly spokesperson told Verywell that about 10% of people who start taking Zepbound for the first time enroll in the self-pay program. This includes people who previously used compounded tirzepatide.

“Congressional action is required to prevent the severe limitations on telehealth that existed before the COVID-19 pandemic from being restored,” said American Medical Association president Bruce A. Scott, MD.

Analysis of more than 30,000 adult ADHD patients reveals significant increases in risk across 13 medical conditions, suggesting the need for comprehensive care protocols beyond standard ADHD management.

Analysis of more than 5 million adolescent insurance claims reveals that gender-affirming medication prescriptions remain exceptionally rare, with peak rates reaching only 140.16 per 100,000 at age 17 for AFAB adolescents.

The preservation of Medicare drug price negotiations alongside the removal of other cost-reduction measures creates a complex landscape for healthcare delivery and patient access.